This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Autosomal recessive agammaglobulinaemia [Swiss type]보통염색체열성 무감마글로불린혈증(스위스형)

ICD-10: D80.0 | Synonyms: autosomal recessive agammaglobulinemia, AR agammaglobulinemia, non-XLA agammaglobulinemia

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Classification issues after the discovery of XLA

After Bruton first described X-linked agammaglobulinemia (XLA) in 1952, cases of agammaglobulinemia in girls or with autosomal inheritance—showing a clinically similar phenotype but not following an X-linked inheritance pattern—were reported sporadically. Despite the absence of BTK gene variants, these cases showed a block in B cell development and severe panhypogammaglobulinemia, just like XLA.

The concept of the Swiss type

In the early literature, Swiss type immunodeficiency referred to severe humoral immunodeficiency with autosomal recessive inheritance described by Swiss researchers. The ICD-10 classification classifies autosomal recessive agammaglobulinemia due to causes other than BTK as the Swiss type.

Sequential identification of causative genes

In 1998, Minegishi et al. reported IGLL1 gene variants, and in 1999 BLNK gene variants, as causes of autosomal recessive agammaglobulinemia. Subsequently, variants in genes such as IGHM, CD79A, CD79B, PIK3R1, and TCF3 were each reported, revealing that defects at various stages of the B cell development pathway cause similar phenotypes.

Recognition in Korea

In Korea, diagnosed cases of BTK-negative agammaglobulinemia began to be reported after the 2000s with the development of immunology and improvements in genetic diagnostic technology. Diagnostic rates are improving with the introduction of next-generation sequencing (NGS)–based primary immunodeficiency panels.

2. Causes

Diverse causative genes

Autosomal recessive agammaglobulinemia is a heterogeneous group of disorders caused by mutations in various genes involved in the B cell development pathway.

IGHM (immunoglobulin heavy chain mu)

Variants in the μ heavy chain gene (IGHM) are the most common cause. The μ heavy chain is a core component of the pre-B cell receptor (pre-BCR), and its deficiency blocks the transition from pro-B to pre-B cells. This block occurs at the same point as in BTK deficiency, and the clinical phenotype is very similar to XLA.

IGLL1 (Lambda5) and CD79A/B

The IGLL1 gene encodes λ5, a component of the surrogate light chain. When it is mutated, the pre-B cell receptor cannot be assembled and B cell development is blocked. CD79A (Igα) and CD79B (Igβ) make up the signaling subunits of the B cell receptor complex, and when they are mutated, BCR signaling is blocked and B cell development stops.

BLNK (B cell linker protein)

BLNK is a downstream signaling molecule of BTK that mediates calcium signaling via PLCγ2 after BCR activation. BLNK deficiency causes a phenotype similar to BTK deficiency. Variants in other genes such as PIK3R1, PIK3CD, and TCF3 have also been reported.

3. Genetics

Autosomal recessive inheritance

All of these disorders follow an autosomal recessive inheritance pattern. Males and females are affected equally, and heterozygous parents are clinically normal. When both parents are carriers, each child has a 25% risk of being affected.

Consanguineous marriage and increased incidence

The incidence of autosomal recessive immunodeficiencies is relatively high in populations with a high frequency of consanguineous marriage (the Middle East, North Africa, some parts of Asia). Primary immunodeficiency cohort studies in Iran, Turkey, Pakistan, and elsewhere report a high proportion of autosomal recessive variants.

Genotype-phenotype correlation

Even within the same causative gene, clinical severity can vary depending on the variant type. Some missense variants of the IGHM gene may show only a mild reduction in B cells owing to residual μ heavy chain expression. Overall, nonsense/deletion variants result in a more severe phenotype.

4. General epidemiology

Worldwide incidence

Autosomal recessive agammaglobulinemia is much rarer than XLA. It accounts for about 5–10% of primary antibody deficiencies worldwide, and about 10–15% of all patients with agammaglobulinemia are estimated to be negative for BTK variants.

Sex distribution

Because of its autosomal recessive inheritance, the male-to-female incidence ratio is nearly equal. This is an important epidemiological difference from XLA (which affects only males), and this disease must be considered when agammaglobulinemia is suspected in a girl.

Status in Korea

In Korea, systematic statistics on patients with BTK-negative agammaglobulinemia are lacking, but with the introduction of gene panel testing, diagnosed cases of patients with IGHM, CD79A/B, and BLNK variants are gradually being reported. The classification of primary immunodeficiencies within the rare disease registration system is being refined.

5. Pathophysiology

Blockade of the common pre-B cell receptor signaling pathway

Autosomal recessive agammaglobulinemia due to various causative genes has a common feature: each causative gene encodes a molecule essential to the pre-B cell receptor (pre-BCR) assembly or signaling pathway. A defect at any step of this pathway blocks B cell development at the pro-B cell stage.

B cell developmental block and immunoglobulin deficiency

The consequences of the B cell developmental block are almost identical to those of XLA. Mature B cells in the peripheral blood are markedly reduced or absent, and all immunoglobulin classes (IgG, IgA, IgM) are severely reduced. T cell development and function are not affected, so cellular immunity is normal.

Differences in the stage of block by causative gene

IGHM variants block development at the pro-B stage because the absence of the μ heavy chain makes pre-BCR assembly impossible. IGLL1 and CD79A/B variants also block development at the same stage because the pre-BCR complex cannot be formed. With BLNK variants, the pre-BCR complex forms but downstream signaling is blocked and development stops. These differences may be associated with the milder phenotype in which a small number of mature B cells are observed with some variants.

6. Symptoms

Age of onset and similarity to XLA

The clinical symptoms of autosomal recessive agammaglobulinemia are very similar to XLA. Recurrent bacterial infections begin after age 6–18 months as maternal antibodies are lost. Recurrent otitis media, sinusitis, pneumonia, sepsis, meningitis, and arthritis are the main clinical manifestations.

Distinguishing point - onset in girls

The most important difference from XLA is that it can also occur in girls. When XLA-like symptoms occur in a girl without a family history, autosomal recessive agammaglobulinemia must be ruled out. In some cases, a milder B cell deficiency than in XLA may be seen, with a small number of residual B cells observed.

Susceptibility to enterovirus infection

As in XLA, chronic enterovirus infection (central nervous system meningoencephalitis, dermatomyositis-like syndrome) can occur. Oral live polio vaccine is absolutely contraindicated.

7. Signs

Physical examination findings

As in XLA, the tonsils and lymph nodes are abnormally small or not palpable. Bronchiectasis, chronic sinusitis, and sequelae of otitis media due to recurrent infections are observed. Growth delay may appear in patients with severe recurrent infections.

Laboratory findings

Serum IgG, IgA, and IgM are all markedly reduced or undetectable. Peripheral blood B cells (CD19+) are markedly reduced or absent. T cell numbers and function are normal.

Differentiation by flow cytometry

In XLA, BTK protein expression is absent in monocytes, but in autosomal recessive agammaglobulinemia, BTK protein expression is normal. This test allows the important differentiation from XLA.

8. Screening

Clinical suspicion

This disease should be suspected in infants of either sex with recurrent bacterial infections. In particular, autosomal recessive agammaglobulinemia must be considered when a clinical picture similar to XLA appears in a girl.

Immunoglobulin quantification and lymphocyte subset analysis

Quantification of serum immunoglobulins (IgG, IgA, IgM) and measurement of lymphocyte subsets (T/B/NK cell proportions and absolute counts) by flow cytometry are the basic screening tests. After absence of B cells and panhypogammaglobulinemia are confirmed, the workup proceeds to BTK protein expression testing and genetic analysis.

KREC testing

Measurement of kappa-deleting recombination excision circles (KREC) is being studied as a potential newborn screening tool for B cell developmental defects, but it has not yet become a clinical standard.

9. Diagnosis

Differential diagnosis process from XLA

In patients in whom absence of B cells and panhypogammaglobulinemia are confirmed by flow cytometry, BTK protein expression testing is performed first. If BTK expression is normal, autosomal recessive agammaglobulinemia is suspected and a causative gene panel test is performed.

NGS-based causative gene panel

A primary immunodeficiency NGS panel including the main genes involved in B cell development (IGHM, IGLL1, CD79A, CD79B, BLNK, PIK3R1, TCF3, etc.) is becoming the standard diagnostic method. If no cause is found on the panel, in-depth investigation by whole-exome or genome analysis is possible.

Functional validation

Functional validation of suspected variants (protein expression, signaling experiments) provides additional evidence for classifying a variant as pathogenic.

10. Treatment

Immunoglobulin replacement therapy

As in XLA, immunoglobulin replacement therapy (IVIG or SCIG) is the standard treatment. The goal is to maintain IgG trough levels of 8 g/L or higher, or 10 g/L or higher when pulmonary complications are present. Treatment must be continued for life.

Infection control and prevention

Early antibiotic treatment of infections, chest physiotherapy for bronchiectasis, and prophylactic antibiotics are considered. Live vaccines are absolutely contraindicated, and inactivated polio vaccine is recommended instead of oral polio vaccine.

Outlook for gene therapy

Research on gene correction or complementation therapy for various causative genes such as IGHM, CD79A/B, and BLNK is under way at the preclinical stage. Clinical application is currently limited.

11. Prognosis

Overall prognosis

Patients receiving regular immunoglobulin replacement therapy can maintain a relatively normal quality of life into adulthood. The overall prognosis is similar to that of XLA. Diagnostic delay and the degree of lung damage before the start of treatment are the key factors determining long-term prognosis.

Major complications and causes of death

Progression of chronic lung disease (bronchiectasis), central nervous system enterovirus infection, and autoimmune complications are the main causes of morbidity and mortality. Complications can be minimized with appropriate IgRT and infection management.

12. Prevention

Genetic counseling

Because inheritance is autosomal recessive, when both parents are carriers the risk to each child is 25%. Screening and genetic counseling for siblings of confirmed patients are recommended. In consanguineous families, carrier testing in advance is desirable.

Prenatal diagnosis

In families in which a causative gene variant has been identified, prenatal diagnosis is possible by fetal genetic testing via CVS or amniocentesis. Implantation of affected embryos can also be prevented through preimplantation genetic testing (PGT-M).

Complication prevention and long-term management

Early diagnosis and early initiation of IgRT, contraindication of live vaccines, early treatment of infections, and regular follow-up of pulmonary function and chest imaging are key to preventing complications. In managing the transition to adulthood, continued IgRT and monitoring of lung disease are important.

13. References

  1. Minegishi Y, Coustan-Smith E, Wang YH, Cooper MD, Campana D, Conley ME. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med. 1998;187(1):71-77.
  2. Minegishi Y, Rohrer J, Coustan-Smith E, et al. An essential role for BLNK in human B cell development. Science. 1999;286(5446):1954-1957.
  3. Dobbs AK, Yang T, Farmer D, Kager L, Parolini O, Conley ME. Cutting edge: a hypomorphic mutation in Igbeta (CD79b) in a patient with immunodeficiency and a leaky defect in B cell development. J Immunol. 2007;179(4):2055-2059.
  4. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199-227.
  5. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96-128.
  6. Abolhassani H, Aghamohammadi A, Hammarstrom L. Newborn screening for primary immunodeficiencies: a population-based approach. Expert Rev Clin Immunol. 2016;12(5):525-538.
  7. van Zelm MC, Reisli I, van der Burg M, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354(18):1901-1912.
  8. Ochs HD, Smith CIE, Puck JM. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. 3rd ed. Oxford University Press; 2013.
  9. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.
  10. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-194.
  11. Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol. 2000;19(2):183-204.
  12. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85(4):193-202.